Web Results

Nucci v. Target Corp. - Fourth District Court of Appeal

www.4dca.org/opinions/Jan 2015/01-07-15/4D14-138.op.pdf

United States Court of Appeals - US Court Of Appeals

media.ca8.uscourts.gov/opndir/14/03/122056P.pdf

Sep 24, 2013 ... v. ABB, Inc.; John W. Cutler, Jr.; Pension Review Committee of ABB, ... (ERISA), 29 U.S.C. § 1001 et seq. ... services to the Plan and the other corporate services Fidelity ... allocation as the funds approached their respective target retirement dates. ..... unreliable testimony of the participants' expert, Al Otto...

Mark J. Girouard - Nilan Johnson Lewis

nilanjohnson.com/people/mark-j-girouard/

Mark excels at analyzing complex legal issues and boiling them down to practical business advice. Having grown up in a newspaper family, he prides himself on ...

Frequent genetic abnormalities of the PI3K/AKT pathway in primary ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC3110626/

May 11, 2011 ... ... sequence was performed using Sequencher® v4.5 (Gene Codes Corp., Ann Arbor, .... PI3K has been suggested as a target for ovarian cancer (Dent, et al. ... significantly greater survival time (59.3 vs.28 months, p=0.036) than those with ..... Giannakakis A, Poulos N, O'Brien-Jenkins A, Katsaros D, et al.

Tussey Amicus Brief, supporting plaintiffs-appellees

www.dol.gov/sol/media/briefs/tussey(A)-06-17-2013.htm

Jun 17, 2013 ... Plaintiffs-Appellees,. v. ABB, Inc. et. al.,. Defendants-Appellants. ... Fidelity's Provision Of Corporate Benefits Outsourcing To ABB. 3. ... Katsaros v. Cody, 744 F.2d 270 (2d Cir. 1984). Leigh v. Engle, 727 F.2d 113 (7th Cir. .... offer participants a "lifecycle" or "target-date" fund (a type ...

Judge Mary M. Lisi

www.plainsite.org/judges/rhode-island-district-court/mary-m-lisi/

... v. Target Corporation ... Granite Trading Corporation et . ... v. Monarch Recovery Management, Inc. et al ... National Education Association Rhode Island et al ...

An emerging role for microRNAs in NF1 tumorigenesis | Human ...

humgenomics.biomedcentral.com/articles/10.1186/1479-7364-6-23

miRNA biogenesis has been reviewed in detail by Ladomery et al. ... (5) Interaction between the miRNA and its target mRNA in the miRISC can cause either translational ... either SYBR Green dye or TaqMan probes (Sigma-Aldrich Corporation, St. Louis, MO, USA) [24]. ..... Ambros V: The functions of animal microRNAs.

Biological and Clinical Significance of MAD2L1 and BUB1, Genes ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0136246

Aug 19, 2015 ... The study conducted by Van's Veer et al [2] identified a 231-gene signature in the initial stage. ... siRNA of human MAD2L1 and BUB1 and negative control ON- TARGET plus ..... Mu L, Tuck D, Katsaros D, Lu L, Schulz V, Perincheri S, et al. .... California (US) corporation #C2354500, based in San Francisco.

Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint ...

journals.plos.org/plosone/article?id=10.1371/journal.pone.0129237

Jun 16, 2015 ... Effector T-cells were added to target tumor cells at varying numbers in a final volume of 0.2 ml ..... Ceschel S, Casotto V, Valsecchi MG, Tamaro P, Jankovic M, et al. .... Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. .... California (US) corporation #C2354500, based in San Francisco.

High-content molecular profiling of T-cell therapy in oncology - Nature

www.nature.com/articles/mto20169

Mar 30, 2016 ... Single target therapy is capable of selecting for and/or inducing .... Zhang, L, Conejo-Garcia, JR, Katsaros, D, Gimotty, PA, Massobrio, M, Regnani, G et al. ..... Snyder, A, Makarov, V, Merghoub, T, Yuan, J, Zaretsky, JM, Desrichard, A et al. ... technology and licensed to Novartis Corporation; former member, ...

More Info

Facebook Photos Not Off-Limits In Target Slip-And-Fall Suit - Law360

www.law360.com

Jan 8, 2015 ... The case is Maria F. Leon Nucci and Henry Leon v. Target Corp. et al, case number 4D14-138 in the District Court of Appeal of the State of ...

Increased Restenosis Rate After Implantation of Drug-Eluting Stents ...

interventions.onlinejacc.org

Katharina M. Katsaros, MD,* Stefan P. Kastl, MD,* Gerlinde Zorn, BSCI,* Gerald ... stents (SES) (Cypher, Cordis Corp., Miami Lake, Florida), ... late lumen loss and the need for target lesion revascularization ... Katsaros et al. ... 276.34 ng/ml vs.

Rational combinations of immunotherapeutics that target discrete ...

www.ncbi.nlm.nih.gov

Sep 23, 2013 ... The GM-CSF fusion is thought to target antigen-loading onto DCs. .... development, INCB024360 (Incyte Corporation, Wilmington, DE, USA) [73-75] and .... administration (concurrent vs sequential, as previously evaluated), the potential .... Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, ...